Fulgent Genetics (FLGT) Net Income towards Common Stockholders (2015 - 2026)

Fulgent Genetics (FLGT) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$24.8 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 115.32% year-over-year to -$24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73.8 million (down 81.01% YoY) and the FY2025 annual result came in at -$60.5 million, down 41.69% from the prior year.
• Net Income towards Common Stockholders fell to -$24.8 million in Q1 2026 per FLGT's latest filing, from -$23.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $153.6 million in Q1 2022, with the low at -$128.1 million in Q4 2023.
• Average Net Income towards Common Stockholders over 5 years is -$9.1 million, with a median of -$13.1 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders slumped 1075.95% in 2023 and surged 95.41% in 2024.
• Fulgent Genetics' Net Income towards Common Stockholders stood at -$24.1 million in 2022, then plunged by 432.27% to -$128.1 million in 2023, then surged by 95.41% to -$5.9 million in 2024, then slumped by 297.72% to -$23.4 million in 2025, then dropped by 6.01% to -$24.8 million in 2026.
• Business Quant data shows FLGT's Net Income towards Common Stockholders at -$24.8 million in Q1 2026, -$23.4 million in Q4 2025, and -$6.6 million in Q3 2025.